A detailed history of Daiwa Securities Group Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 2,852 shares of NTLA stock, worth $43,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,852
Previous 2,883 1.08%
Holding current value
$43,122
Previous $65,000 9.23%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$19.72 - $27.36 $611 - $848
-31 Reduced 1.08%
2,852 $59,000
Q2 2024

Aug 07, 2024

SELL
$20.02 - $27.22 $100 - $136
-5 Reduced 0.17%
2,883 $65,000
Q1 2024

May 02, 2024

SELL
$23.82 - $32.8 $4,001 - $5,510
-168 Reduced 5.5%
2,888 $79,000
Q4 2023

Jan 31, 2024

BUY
$23.16 - $32.34 $18,365 - $25,645
793 Added 35.04%
3,056 $93,000
Q2 2023

Jul 31, 2023

BUY
$34.58 - $46.03 $2,213 - $2,945
64 Added 2.91%
2,263 $92,000
Q1 2023

May 02, 2023

BUY
$33.3 - $44.82 $12,320 - $16,583
370 Added 20.23%
2,199 $82,000
Q4 2022

Feb 06, 2023

BUY
$33.21 - $62.69 $3,387 - $6,394
102 Added 5.91%
1,829 $64,000
Q3 2022

Nov 02, 2022

SELL
$53.92 - $71.7 $24,102 - $32,049
-447 Reduced 20.56%
1,727 $97,000
Q2 2022

Aug 09, 2022

BUY
$38.49 - $76.21 $75,324 - $149,142
1,957 Added 901.84%
2,174 $113,000
Q4 2021

Feb 03, 2022

SELL
$100.76 - $138.36 $3,526 - $4,842
-35 Reduced 13.89%
217 $26,000
Q3 2021

Nov 05, 2021

BUY
$132.37 - $176.78 $15,619 - $20,860
118 Added 88.06%
252 $34,000
Q1 2021

May 03, 2021

BUY
$46.59 - $83.68 $1,071 - $1,924
23 Added 20.72%
134 $11,000
Q4 2020

Feb 04, 2021

SELL
$18.83 - $63.53 $3,332 - $11,244
-177 Reduced 61.46%
111 $6,000
Q2 2019

Jul 24, 2019

BUY
$13.88 - $18.41 $749 - $994
54 Added 23.08%
288 $5,000
Q1 2018

May 02, 2018

BUY
$19.43 - $34.95 $4,546 - $8,178
234 New
234 $5,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.15B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.